Aminoxy Acid Compounds for Mitochondrial CSC Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are ineffective against cancer stem cells (CSCs) due to their resistance to conventional chemotherapies and radiotherapies, leading to tumor metastasis and relapse, and existing compounds like salinomycin face limitations due to drug transporter systems in certain cancer cells.
Innovation Solution
Development of synthetic, small molecules, such as aminoxy acid-based compounds, that selectively target CSCs by modulating mitochondrial membrane potential, inducing reactive oxygen species production, and attenuating mitochondrial respiration, thereby inducing CSC death with high selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapies and radiotherapies are used to treat cancer, then cancer cells can be treated, but cancer stem cells remain resistant leading to tumor metastasis and relapse
Solution Approach 1:
The patent changes the molecular target parameter from conventional chemotherapy targets to mitochondrial-specific targets (mtDNA, mitochondrial membranes, respiratory chain complexes). This parameter change enables selective targeting of CSCs while sparing normal cells, resolving the contradiction between therapeutic effectiveness and CSC resistance.
Solution Approach 2:
The patent introduces mitochondrial dysfunction as an intermediary mechanism between the drug and CSC death. By targeting mitochondrial components (mtDNA replication, membrane potential, respiratory chain), the drug indirectly kills CSCs through a cascade of mitochondrial failures, overcoming direct resistance to conventional therapies.
2Reliability
If salinomycin is used to inhibit CSCs, then mitophagy and ATP depletion occur, but drug transporter systems in ovarian cancer cells escape toxicity
Solution Approach 1:
The patent extracts the mechanism of action from cytoplasmic ATP depletion (salinomycin's main mechanism) and relocates it to mitochondrial-specific targets. By targeting mitochondrial DNA replication and respiratory chain complexes directly within mitochondria, the drug bypasses cytoplasmic drug transporters that enable escape in ovarian cancer cells.
Solution Approach 2:
Instead of relying on ATP depletion as the primary mechanism (which allows transporter-mediated escape), the patent inverts the approach by directly targeting mitochondrial structures and processes. This inversion makes the mechanism less susceptible to cytoplasmic drug transporters, as the target is located within the mitochondrial compartment.
3Reliability
If mitochondria targeting compounds are used to attack CSCs, then mitochondrial mass and membrane potential are affected, but selectivity over normal cells is limited
Solution Approach 1:
The patent applies local quality by targeting specific mitochondrial components (mtDNA, respiratory chain complexes) that have unique functional characteristics in CSCs versus normal cells. By focusing on these specific local targets within the mitochondrion, the drug achieves selective CSC killing while minimizing effects on normal cells that have different mitochondrial characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aminoxy acid-based compounds demonstrate up to 60-fold selectivity in inducing CSC death over cancer and normal cells, reducing CSC populations, sphere-forming ability, and in vivo tumor seeding, while affecting mitochondrial functions like depolarization and superoxide production.
Implementation Method 1
modulating mitochondrial membrane potential
Implementation Method 2
inducing reactive oxygen species production
Implementation Method 3
attenuating mitochondrial respiration
Data Source
AI summary
The disclosed invention is generally in the field of synthetic small molecules and their use as drug, in particular in the treatment of cancer. Also provided is a method of inhibiting cancer stem cells. Also provided is a method for treatment of cancers and other diseases by affecting mitochondrial functions. Also provided is a method of making and using of the compounds.